Verrica Pharmaceuticals Inc. went public Friday morning, raising $75 million in the first initial public stock offering by an area life sciences company this year.

The company, which is focused on developing treatments for skin diseases, sold five million shares of common stock at $15, writes John George at bizjournals.com.

[uam_ad id=”54865″]

The company’s lead product candidate, VP-102, is currently being evaluated in two late-stage clinical trials for the treatment of Molluscum contagiosum, a skin infection caused by a virus that produces benign raised bumps, or lesions, on the upper layers of the skin.

To read the full story, click here.

To see the image above and related images click here. 

[uam_ad id=”61456″]